- Home
- NEWS
- REGIONAL
- THIS WEEK'S PAPER
- BLOGS
- Multimedia
- OPINION
- A&E
- LISTS
- PEOPLE
- EVENTS
- Classifieds
- Subscribe
Health Care Businesses
Orthopedic startups attracting big money
June 9, 2012
J.K. WallThe Warsaw area is well-known as the home of gigantic orthopedic implant companies and their suppliers. But now a handful
of startups have been able to raise nearly $25 million in equity investments despite the recession—putting a bit more
fuel into a fairly stagnant entrepreneurial sector.
MoreHouse swipes at health law with repeal of medical device tax
June 8, 2012
Republicans in the U.S. House joined with 37 Democrats to pass a bill repealing a medical-device tax, chipping away at the
2010 health-care law in a victory for companies including Indiana-based Zimmer Holdings Inc. and Boston Scientific Corp.
MoreGood cholesterol may not lower heart risk, study suggests
May 17, 2012
Bloomberg NewsRaising good cholesterol, a goal pursued by Eli Lilly and Co. as the next milestone in cardiac care, may not cut heart-attack
risk, says a study that challenges the development of drugs that may someday generate billions of dollars in sales.
MoreU.S. losing drug-research jobs to other countries
May 17, 2012
Bloomberg NewsEli Lilly and other big pharmaceutical companies are creating thousands of research jobs overseas as countries led by Singapore,
Ireland and South Africa boost incentives.
MoreLilly unlikely to gain from Plavix patent loss, analyst says
May 17, 2012
Bloomberg NewsIndianapolis-based Eli Lilly and Co. and London-based AstraZeneca Plc aren't expected to have an easier time gaining more
of the market for blood thinners dominated by Bristol-Myers Squibb Co.’s Plavix after the drug loses U.S. patent protection
Thursday.
MoreCancer tools help Roche with Alzheimer's drug
May 13, 2012
Bloomberg NewsTreatments for central nervous system diseases have a huge potential payoff, analysts say. A hint of whether the gamble may
pay off is due in the second half of this year, as Eli Lilly and Co. and Pfizer Inc. announce results for Alzheimer’s drugs
that attack the same protein as Roche’s experimental drug.
MoreRoche scraps hoped-for cholesterol blockbuster
May 7, 2012
Associated PressA second experimental cholesterol medicine in a once-promising class of drugs meant to replace blockbusters such as Lipitor
has failed in testing, casting doubt on whether any of the drugs will ever make it to pharmacies. Eli Lilly is developing
a similar drug.
MoreOnce-promising Arcadia Resources closing doors
May 4, 2012
Scott OlsonThe health care company that once promised to create 900 jobs in central Indiana has agreed to cease operations after a major
lender moved to foreclose on the struggling Indianapolis-based business.
MoreArrests made in $80M Lilly prescription drug heist
May 3, 2012
IBJ Staff and Associated Press, Bloomberg NewsAuthorities have arrested two Cuban brothers in the 2010 theft of about $80 million in Eli Lilly and Co. prescription drugs
from a Connecticut warehouse, a robbery described as one of the biggest pharmaceutical heists in history, the U.S. attorney's
office said Thursday.
MoreLilly letting U.S. researchers test failed compounds for new uses
May 3, 2012
Bloomberg NewsMore than 20 compounds that Eli Lilly and Co., Pfizer Inc. and AstraZeneca Plc failed to turn into drugs will be tested by
U.S.-sponsored scientists in a $20 million program to see if they’ll work against ailments they weren’t aimed
at previously.
MoreLilly capitalizing on demand for testosterone drugs
May 2, 2012
Bloomberg NewsThe market for testosterone-replacement treatments is growing, but health experts say overuse of the drugs can be dangerous.
MoreEli Lilly's Cialis faces faster-acting competition
April 30, 2012
IBJ Staff and Bloomberg NewsA Vivus Inc. pill that is supposed to provide erections within 15 minutes, about half the time or less than Eli Lilly and
Co.'s Cialis or Pfizer Inc.’s Viagra, has received U.S. regulatory approval.
MoreLilly tops analyst expectations despite shrinking profit, revenue
April 25, 2012
J.K. WallLilly's quarterly sales and profit fell due to lost patent protection on Gemzar and Zyprexa. But sales of antidepressant Cymbalta,
blood thinner Effient, animal health products and sales in China grew by 20 percent or more.
MoreIntegra Specialty Hospital in Muncie closing
April 20, 2012
Seventy-two employees will lose their jobs when the 32-bed long-term-care facility shuts down on June 17. The company that
operates the hospital did not provide a reason for the closing.
MoreIndy is poster child (again) for medical arms race
April 16, 2012
J.K. WallIndianapolis was highlighted in a new national study because its hospitals have been particularly aggressive at expanding
their geographic reach—raising concerns among health insurers and even hospitals themselves that new medical facilities
and market power can only lead to higher prices.
MoreIs health care bubble about to burst?
April 16, 2012
J.K. WallCitigroup economist writes that U.S. health care sector "reminds us somewhat ominously of the bubble in housing finance"
because public spending is fueling private profits.
MorePoison pills remain as Lilly shareholder vote falls short
April 16, 2012
J.K. WallThe proposal garnered support from the owners of 62 percent of Eli Lilly's outstanding shares. To pass, the proposal needed
approval from the owners of 80 percent of Lilly’s shares.
MoreLilly CEO says cost-cutting won’t solve sales losses
April 13, 2012
Bloomberg NewsEli Lilly and Co., facing generic competition to two of its top drugs, needs to rely on new medicines rather than cost-cutting
to overcome the revenue loss, CEO John Lechleiter said Thursday in Boston at the annual meeting of the Pharmaceutical Research
and Manufacturers of America.
MoreLilly wins FDA approval for Alzheimer's imaging agent
April 9, 2012
J.K. WallThe agent, called Amyvid, is not expected to produce high-dollar sales for Lilly, but it could help to identify patients with
Alzheimer’s—and those without it—earlier, perhaps improving treatment and focusing research efforts.
MoreExpress Scripts-Medco deal approved by U.S. regulators
April 2, 2012
Bloomberg NewsExpress Scripts Inc.’s $29.1 billion bid for rival drug benefit manager Medco Health Solutions Inc. won unconditional
approval from U.S. antitrust regulators, clearing the way to create the biggest manager of prescription-drug benefits for
corporate and government clients.
MoreLilly receives Europe's OK for new Byetta use
March 23, 2012
IBJ Staff and Associated Press, Associated PressEuropean regulators have approved an expanded use for the diabetes treatment Byetta, developed by Eli Lilly and Co. and Amylin
Pharmaceuticals Inc. The FDA approved the same expanded use last fall.
MoreLilly to focus on cancer, diabetes in China, CEO says
March 20, 2012
Bloomberg NewsIndianapolis-based Eli Lilly and Co. will introduce “over a dozen” new products in China in the next five years,
focusing on “unmet needs” such as cancer and diabetes, CEO John Lechleiter said this week.
MoreExpress Scripts’ Medco deal may be delayed by potential suit
March 19, 2012
IBJ Staff and Bloomberg NewsExpress Scripts Inc.’s bid to acquire Medco Health Solutions Inc. and create the largest U.S. pharmacy-benefits manager
may be delayed by a lawsuit being considered by five states.
MoreFTC asks critics of Express Scripts-Medco deal for ideas
March 10, 2012
Bloomberg NewsTwo pharmacy groups opposing Express Scripts Inc.’s proposed acquisition of Medco Health Solutions Inc. said they were
asked by the U.S. Federal Trade Commission to suggest ways to revise the $29.1 billion deal so it wouldn’t harm competition.
MoreLilly to try again to remove poison-pill provisions
March 6, 2012
J.K. WallEli Lilly and Co.'s board is once again recommending the removal of a provision that makes the company an almost impossible
target for hostile takeovers. The same proposal has fallen slightly short at each of the past two annual shareholder meetings.
More
Sponsored by
ADVERTISEMENT
on Facebook & Twitter
on Facebook & Twitter
 Follow IBJ's Tweets on these topics: |
||
| @IBJNews | @Propertylines | @IBJTheScore |
| @IBJArts | @IBJHealthcare | @IBJDining |
| @IBJLists | @IBJSmallbiz | |
ADVERTISEMENT
Back to TopCopyright © All Rights Reserved. Privacy Policy | Terms of Use.
Design, CMS, Hosting & Web Development :: ePublishing.
Additional Hosting & Delivery by
My city lost population. My neighborhood lost population. I hope the trend continues. Urban/suburban/rural trends point to more affluent city centers, more Balkanized (economically) suburbs and a rural America of 'Great Camps' - retreats for the wealthy.
Irvington is up and coming much like Fountain Square. We would love to have something like this in our neighborhood!
Why do we care who has submitted proposals if we can't review the proposals? It's publicly owned land, but the public has zero say in what gets chosen to be built there. Yep, that sounds about right.
Perhaps May 21 is "Evangelical Day" over at the IBJ?
I don't know what's more depressing: that this passes for a defensible elective in a publicly funded SCIENCE class, or that more than half of the posters here are defending this charlatan. Intelligent design is creationism. Creationism is religion. Yes, we have freedom of religion, which deserves to be protected. Now someone kindly show Professor Hedin his freedom by escorting him over to the Religion department at BSU. Carry on.